Fiocruz and Sinovac announce cooperation in vaccine research and development

At a meeting with the Vice President of the Republic and Minister of Development, Industry and Commerce Geraldo Alckmin, in Beijing, Sinovac announced that it will invest US$ 100 million in the development of cell therapy, vaccine production and monoclonal antibodies in Brazil. Sinovac and Fiocruz also announced their intention to cooperate in the research and development of vaccines to tackle health crises.

Alckmin celebrated the partnership with Fiocruz, recalling that Sinovac had previously collaborated with Brazil, specifically the Butantan Institute. "I took Coronavac," said the Vice President, citing the immunizer that helped save thousands of Brazilians during the COVID-19 pandemic. "Science helps the world and we have to advance even further, we have to work together, and so I welcome Sinovac's willingness to invest in Brazil."

The two institutions have begun negotiations to jointly strengthen their roles as official representatives of Brazil and China to make access to immunizers in Brazilian territory more equitable. During the World Health Organization assembly, which took place in Geneva in May this year, the BRIC ministries of health reaffirmed their commitment to this important initiative for global health.

During the COVID-19 pandemic, Sinovac supplied Coronavac to the Brazilian government. At the time, 110 million doses were administered in the country. In addition to Brazil, the Chinese pharmaceutical company has supplied around 3 billion vaccines to 80 countries.